Despite consistent recommendations and growing clinical evidence, uptake of SGLT2i and GLP1 RA therapies in people with type 2 diabetes and cardiorenal comorbidities has been slow. There is also relatively little research on ethnic differences in those starting second-line therapy. This is an omission, as ethnic minority groups have higher rates of morbidity and mortality associated with type 2 diabetes.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- From symptom to diagnosis
Oncology – Thymoma
- Patient-centered rounds in medicine
Aligning care with the patient
- Shared decision making
Participatory decision-making using the example of diets for type 1 diabetes
- Migraine and vascular regulation
CGRP-targeted migraine therapies for vascular risk patients
- Pediatric multiple sclerosis
Early high efficacy as the key to improving prognosis
- Case report, molecular basis and therapeutic implications
HER2-positive colorectal carcinoma with invasive micropapillary component
- Wound Care
Chronically infected wound on the lower leg – a case report
- From symptom to diagnosis